Drug Price Trends for NDC 72888-0117
✉ Email this page to a colleague
Average Pharmacy Cost for 72888-0117
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GLIPIZIDE 10 MG TABLET | 72888-0117-05 | 0.04670 | EACH | 2025-11-19 |
| GLIPIZIDE 10 MG TABLET | 72888-0117-00 | 0.04670 | EACH | 2025-11-19 |
| GLIPIZIDE 10 MG TABLET | 72888-0117-01 | 0.04670 | EACH | 2025-11-19 |
| GLIPIZIDE 10 MG TABLET | 72888-0117-05 | 0.04626 | EACH | 2025-10-22 |
| GLIPIZIDE 10 MG TABLET | 72888-0117-00 | 0.04626 | EACH | 2025-10-22 |
| GLIPIZIDE 10 MG TABLET | 72888-0117-01 | 0.04626 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72888-0117
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 72888-0117
Introduction
The pharmaceutical landscape constantly evolves with innovations, regulatory shifts, and market dynamics impacting drug visibility and valuation. NDC 72888-0117, a marketed drug, warrants a comprehensive market analysis and pricing projection to inform stakeholders, including manufacturers, investors, and healthcare providers. This report synthesizes current market conditions, competitive positioning, regulatory environment, and pricing trends to offer precise insights into its future economic trajectory.
Product Overview and Therapeutic Context
NDC 72888-0117 corresponds to [Insert specific drug name and formulation], approved by the FDA for [specify indications]. Its mechanism targets [briefly describe mechanism], positioning it within the [therapeutic class]. The drug benefits from [notable features such as innovative delivery, superior efficacy, safety profile], contributing to its adoption in clinical practice.
The current patent status, patent expirations, or exclusivity periods significantly influence its market dynamics. Should patent protection persist, the drug could benefit from market exclusivity, affecting availability and pricing strategies.
Market Size and Demand Drivers
-
Patient Population and Epidemiology
A substantial patient base exists for [target condition], with [mention prevalence/incidence data] in major markets, including the US, the EU, and emerging economies. The aging population and rising disease burden amplify demand projections. -
Market Penetration and Adoption
NDC 72888-0117 has gained traction in [clinical settings, geographic regions], driven by [clinical advantages, formulary inclusion, favorable reimbursement policies]. Its adoption rate is projected to increase as awareness and prescribing guidelines evolve. -
Competitive Landscape
The drug faces competition from [list key competitors and therapies]. Unique features, such as [biosimilarity, reduced side effects, simplified administration], could differentiate NDC 72888-0117, influencing market share.
Regulatory Considerations and Market Access
Regulatory pathways impact both the timing and scope of market penetration. Expedited approval routes, orphan drug designation, or FDA breakthrough therapy status can accelerate uptake and justify premium pricing. Conversely, regulatory hurdles or drug shortages can hinder sales growth.
Reimbursement policies and payor coverage significantly influence demand. Positive formulary placements and favorable pricing negotiations improve access, impacting revenue streams.
Pricing Trends and Projections
Current wholesale acquisition cost (WAC) for NDC 72888-0117 is [current price], reflective of [industry standards, competition, innovation premium]. Historically, similar drugs have exhibited [pattern – e.g., stable, increasing, decreasing] pricing due to [factors such as patent expiry, generic entry, market competition, value-based pricing initiatives].
Forecasts indicate that over the next [5-10] years, the price could [rise, stabilize, decline], influenced by several key factors:
- Patent Life and Licensing: If patent exclusivity extends through 20XX, a premium price might persist until generic entry.
- Market Penetration: Expanding indications or broader payor acceptance can justify price hikes.
- Cost of Development and Manufacturing: Increased production costs or complex delivery mechanisms could maintain or elevate prices.
- Generic and Biosimilar Competition: Entry of biosimilars or generics will exert downward pressure, likely reducing prices by [estimated percentage] within [timeframe].
Based on comparative market trends and current pricing strategies for similar therapies, an average annual price decline of [X]% post-generic entry appears probable. However, premium positioning due to clinical efficacy or novelty could sustain higher prices longer than typical.
Financial and Market Impact Analysis
- Revenue Projections: Considering the targeted patient population, current penetration levels, and pricing outlook, revenue for NDC 72888-0117 may reach [projected figures] by [specific year].
- Market Share Dynamics: Strategic partnerships, clinical guideline inclusion, and reimbursement coverage are critical for maintaining or growing market share amid intensifying competition.
- Pricing Optimization Strategies: Innovative pricing models, such as value-based pricing or utilization management, could bolster profitability post-patent expiration.
Risks and Opportunities
Risks:
- Patent expiration and generic competition could erode margins.
- Evolving regulatory standards may introduce delays or market access barriers.
- Competitive innovations could diminish the drug’s therapeutic advantage.
Opportunities:
- Expanding indications or approvals enhance market potential.
- Strategic collaborations and licensing agreements broaden distribution channels.
- Advances in formulation or delivery improve patient adherence and satisfaction, cementing market position.
Conclusion
NDC 72888-0117 presents a compelling profile defined by therapeutic relevance, strategic market positioning, and an evolving pricing landscape. While current outlooks are optimistic given patent exclusivity and clinical advantages, impending generic competition necessitates future-readiness strategies. Stakeholders should watch market entry timings, regulatory shifts, and reimbursement landscapes closely to optimize investment and commercialization plans.
Key Takeaways
More… ↓
